Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Days Payable Chart
MEX:LABB vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Days Payable distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Days Payable falls into.
Genomma Lab InternacionalB de CV Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV (MEX:LABB) has a Days Payable of 100.21 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is near median its historical median of 98.02. Over the past decade, Genomma Lab InternacionalB de CV's Days Payable has ranged from 85.53 to 144.56. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #413 out of 925 companies in the Drug Manufacturers industry, placing it in the top 44.6%.
Is Genomma Lab InternacionalB de CV's Days Payable too high?
Genomma Lab InternacionalB de CV's current Days Payable of 100.21 is near median its 10-year median of 98.02. Over the past 10 years, this metric has ranged from a low of 85.53 to a high of 144.56. The Drug Manufacturers industry median Days Payable is 89.79. Genomma Lab InternacionalB de CV's value of 100.21 is 11.6% above this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #413 out of 925 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #413 out of 925 companies for Days Payable. This puts Genomma Lab InternacionalB de CV in the upper half of its industry. The industry median Days Payable is 89.79. Genomma Lab InternacionalB de CV's value of 100.21 is 11.6% above this benchmark. Historically, Genomma Lab InternacionalB de CV's own Days Payable has ranged from 85.53 to 144.56 over the past decade. While the company's 10-year median is 98.02 vs. the industry median of 89.79, Genomma Lab InternacionalB de CV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 89.79, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current Days Payable of 100.21 is 11.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Days Payable is 89.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Days Payable is 100.21, which is near median its own 10-year median of 98.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.13, compared to a current price of MXN14.37 — trading 16.1% below its estimated fair value. The current Days Payable is 100.21, which is near median its 10-year median of 98.02 and 11.6% above the Drug Manufacturers industry median of 89.79. Genomma Lab InternacionalB de CV's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Days Payable is 100.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN14.37 is trading 16.1% below its estimated GF Value™ of MXN17.13.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Days Payable: 100.21 (near median its 10-year median of 98.02)
GF Value™: MXN17.13 vs. price of MXN14.37 (16.1% below fair value)
Industry Position: 11.6% above the Drug Manufacturers median (#413 of 925)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
59GF Score
Get the complete analysis for MEX:LABB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
